基础医学与临床 ›› 2015, Vol. 35 ›› Issue (11): 1567-1571.

• 短篇综述 • 上一篇    下一篇

表皮生长因子受体Ⅲ型突变体在卵巢癌中检测及靶向治疗的研究进展

孙平风,傅芬   

  1. 南昌大学第二附属医院
  • 收稿日期:2015-04-16 修回日期:2015-06-29 出版日期:2015-11-05 发布日期:2015-11-03
  • 通讯作者: 孙平风 E-mail:523813958@qq.com
  • 基金资助:
    宫颈癌中EGFR基因突变与磷酸化信号转导蛋白表达的意义

Progress in the detection and targeted therapy of epidermal growth factor receptor variant III in ovarian cancer

,   

  • Received:2015-04-16 Revised:2015-06-29 Online:2015-11-05 Published:2015-11-03

摘要: 表皮生长因子受体III型突变体(EGFRvIII)作为最常见的表皮生长因子受体(EGFR)基因突变类型,只表达于恶性肿瘤,而不表达于正常组织中,是肿瘤特异性标志物,可作为卵巢癌靶向治疗的靶点。

关键词: 表皮生长因子受体, 表皮生长受体III型突变体, 卵巢癌, 靶向治疗

Abstract: The epidermal growth factor receptor variant III (EGFRvIII) also known as the most common mutant form of EGFR is a tumor-specific mutation, hasn’t yet been detected in normal tissues. It is regarded as a tumor-specific gene and offers a new way for targeted therapy of ovarian cancer.

Key words: epidermal growth factor receptor, epidermal growth factor receptor variant III, ovarian cancer, targeted treatment

中图分类号: